Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
- Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program
- Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers
Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, today announces a license agreement with Duality Biologics (“Duality”), a clinical-stage biotech company focused on discovering and developing a pipeline of ADCs targeting cancers and autoimmune diseases.
